JP2006513695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513695A5 JP2006513695A5 JP2004513326A JP2004513326A JP2006513695A5 JP 2006513695 A5 JP2006513695 A5 JP 2006513695A5 JP 2004513326 A JP2004513326 A JP 2004513326A JP 2004513326 A JP2004513326 A JP 2004513326A JP 2006513695 A5 JP2006513695 A5 JP 2006513695A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- mab
- pam4
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 54
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 11
- 238000001514 detection method Methods 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 9
- 102000037865 fusion proteins Human genes 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 5
- 102100034256 Mucin-1 Human genes 0.000 claims 5
- 239000002872 contrast media Substances 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000000032 diagnostic agent Substances 0.000 claims 4
- 229940039227 diagnostic agent Drugs 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 108010063954 Mucins Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 238000002604 ultrasonography Methods 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 150000001553 barium compounds Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 150000002259 gallium compounds Chemical class 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- -1 hematopoietic factor Proteins 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 150000002497 iodine compounds Chemical class 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 150000003476 thallium compounds Chemical class 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38831402P | 2002-06-14 | 2002-06-14 | |
| US60/388,314 | 2002-06-14 | ||
| PCT/GB2003/002593 WO2003106495A2 (en) | 2002-06-14 | 2003-06-16 | MONOCLONAL ANTIBODY hPAM4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010092200A Division JP5155356B2 (ja) | 2002-06-14 | 2010-04-13 | モノクローナル抗体ｈＰＡＭ４ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006513695A JP2006513695A (ja) | 2006-04-27 |
| JP2006513695A5 true JP2006513695A5 (enExample) | 2006-08-10 |
| JP5139626B2 JP5139626B2 (ja) | 2013-02-06 |
Family
ID=29736456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004513326A Expired - Fee Related JP5139626B2 (ja) | 2002-06-14 | 2003-06-16 | モノクローナル抗体ｈＰＡＭ４ |
| JP2010092200A Expired - Fee Related JP5155356B2 (ja) | 2002-06-14 | 2010-04-13 | モノクローナル抗体ｈＰＡＭ４ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010092200A Expired - Fee Related JP5155356B2 (ja) | 2002-06-14 | 2010-04-13 | モノクローナル抗体ｈＰＡＭ４ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7282567B2 (enExample) |
| EP (2) | EP1519958B1 (enExample) |
| JP (2) | JP5139626B2 (enExample) |
| KR (1) | KR101143035B1 (enExample) |
| CN (2) | CN1675245B (enExample) |
| AU (2) | AU2003277087B2 (enExample) |
| BR (1) | BR0311799A (enExample) |
| CA (1) | CA2489467C (enExample) |
| ES (1) | ES2524767T3 (enExample) |
| MX (1) | MXPA04012656A (enExample) |
| WO (1) | WO2003106495A2 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| JP2005507659A (ja) * | 2001-10-15 | 2005-03-24 | イミューノメディクス、インコーポレイテッド | 直接ターゲッティング結合タンパク質 |
| US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US9599619B2 (en) | 2002-06-14 | 2017-03-21 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| US9238081B2 (en) * | 2002-06-14 | 2016-01-19 | Immunomedics, Inc. | Detection of early-stage pancreatic adenocarcinoma |
| US8821868B2 (en) | 2002-06-14 | 2014-09-02 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2595778A1 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| EP3332808B1 (en) | 2005-03-03 | 2020-09-09 | Immunomedics Inc. | Humanized l243 antibodies |
| JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| DK1875244T3 (en) * | 2005-03-30 | 2019-04-29 | Minerva Biotechnologies Corp | Proliferation of MUC1-Expressing Cells |
| JP2008543276A (ja) * | 2005-03-30 | 2008-12-04 | ミネルバ バイオテクノロジーズ コーポレーション | Ｍｕｃ１発現細胞の増殖 |
| US20130039861A1 (en) * | 2005-04-06 | 2013-02-14 | Immunomedics, Inc. | Dye Conjugated Peptides for Fluorescent Imaging |
| EP2674440B1 (en) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| EP2623610B1 (en) * | 2006-02-10 | 2015-04-29 | Life Technologies Corporation | Labeling and detection of post translationally modified proteins |
| CA2647449C (en) * | 2006-03-27 | 2017-05-16 | Medimmune Limited | Binding member for gm-csf receptor |
| EP2083868A2 (en) * | 2006-10-04 | 2009-08-05 | Københavns Universitet | Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| US7777877B2 (en) * | 2006-10-20 | 2010-08-17 | California Institute Of Technology | High efficiency coupling optics for pumping and detection of fluorescence |
| JP5859202B2 (ja) * | 2007-05-21 | 2016-02-10 | アルダーバイオ・ホールディングズ・エルエルシー | 新規のウサギ抗体ヒト化方法及びヒト化ウサギ抗体 |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| SI3187506T1 (sl) | 2007-05-21 | 2019-08-30 | Alderbio Holdings Llc | Protitelesa proti IL-6 in njihova uporaba |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8178101B2 (en) * | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| KR20110013409A (ko) * | 2008-05-23 | 2011-02-09 | 삼성전자주식회사 | 항체-펩티드 융합 상승체 |
| US8489177B2 (en) * | 2008-07-16 | 2013-07-16 | Dilon Technologies, Inc. | Fiducial marker and method for gamma guided stereotactic localization |
| JP5919604B2 (ja) * | 2008-08-08 | 2016-05-18 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 抗膵癌抗体 |
| JP2012504961A (ja) * | 2008-10-06 | 2012-03-01 | ミネルバ バイオテクノロジーズ コーポレーション | Ｍｕｃ１＊抗体 |
| JP2012505636A (ja) | 2008-10-09 | 2012-03-08 | ミネルバ バイオテクノロジーズ コーポレーション | 細胞において多能性を誘導する方法 |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| PL3939617T3 (pl) | 2009-02-13 | 2025-03-17 | Immunomedics, Inc. | Związki pośrednie do wytwarzania koniugatów z wiązaniem rozszczepialnym wewnątrzkomórkowo |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| CN110470835A (zh) | 2009-03-24 | 2019-11-19 | 生物概念股份有限公司 | 细胞捕获和分析的装置和方法 |
| US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
| CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| EP2504030A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP |
| CA2782194C (en) * | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
| ES2547142T5 (es) | 2010-02-08 | 2021-12-09 | Regeneron Pharma | Cadena ligera común de ratón |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| EP2643018B1 (en) | 2010-11-23 | 2020-10-14 | AlderBio Holdings LLC | Anti-il-6 antibodies for the treatment of oral mucositis |
| CA2827076A1 (en) * | 2011-02-15 | 2012-08-23 | Immumomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| CA2830503A1 (en) | 2011-03-17 | 2012-09-20 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| CA2833477A1 (en) | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
| JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
| IL273982B2 (en) | 2011-08-05 | 2023-03-01 | Regeneron Pharma | Humanized mice possess a universal light chain |
| US9056910B2 (en) | 2012-05-01 | 2015-06-16 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| RU2014153674A (ru) * | 2012-06-05 | 2016-07-27 | Регенерон Фармасьютикалз, Инк. | Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| WO2014028560A2 (en) | 2012-08-14 | 2014-02-20 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| BR112015013444B1 (pt) | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | Uso de um imunoconjugado |
| US9844607B2 (en) * | 2013-02-05 | 2017-12-19 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| EP2774930A1 (en) | 2013-03-07 | 2014-09-10 | Aptenia S.R.L. | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. |
| US9452228B2 (en) | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
| CA2899811A1 (en) * | 2013-04-01 | 2014-10-09 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treament of pancreatic cancer |
| CN105829893A (zh) * | 2013-06-14 | 2016-08-03 | 西班牙格拉纳达大学 | 用于胰腺癌诊断及治疗响应的生物标记物 |
| SG11201602249RA (en) | 2013-10-18 | 2016-05-30 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CA2934617A1 (en) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with kinesin spindle protein (ksp) |
| EP3107577B1 (en) | 2014-02-21 | 2024-03-20 | IBC Pharmaceuticals, Inc. | Disease therapy by inducing immune response to trop-2 expressing cells |
| EP3110445A4 (en) | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| BR112016021572A2 (pt) | 2014-03-21 | 2017-10-03 | Regeneron Pharma | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação |
| WO2015153912A1 (en) | 2014-04-03 | 2015-10-08 | Igm Biosciences, Inc. | Modified j-chain |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
| EP3160504B1 (en) | 2014-06-24 | 2020-09-16 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| CN105334207A (zh) * | 2014-08-15 | 2016-02-17 | 上海中信国健药业股份有限公司 | 一种针对egfr靶向治疗药物的生物学活性检测方法 |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| JP7080055B2 (ja) | 2014-09-08 | 2022-06-03 | ルタナ ゲーエムベーハー | 細胞の細胞質への分子の送達のための構築物 |
| KR20240135877A (ko) | 2015-03-04 | 2024-09-12 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄ20 결합 분자 및 그의 용도 |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| EP3286224A4 (en) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| US10912767B2 (en) * | 2015-04-27 | 2021-02-09 | The Regents Of The University Of Colorado, A Body Corporate | Anthracycline prodrugs and methods of making and using the same |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| CN107735104B (zh) | 2015-06-25 | 2022-05-03 | 免疫医疗公司 | 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善 |
| EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| HK1252791A1 (zh) | 2015-09-30 | 2019-06-06 | Igm Biosciences, Inc. | 具有经修饰的j链的结合分子 |
| DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| JP6976249B2 (ja) * | 2015-11-23 | 2021-12-08 | サンガモ セラピューティクス， インコーポレイテッド | 免疫を工学操作するための方法および組成物 |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| CN107213479B (zh) | 2017-06-22 | 2018-12-28 | 苏州杰纳生物科技有限公司 | 一种包含过氧化氢酶的组合物及用途 |
| CN111542324B (zh) * | 2018-02-11 | 2023-09-12 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
| WO2020064847A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| CN111362926B (zh) * | 2018-12-26 | 2021-04-30 | 联宁（苏州）生物制药有限公司 | 一种用于抗体偶联药物的中间体cla-sn38的合成方法及其中间体 |
| CN116390772A (zh) | 2020-07-07 | 2023-07-04 | 博泰康医药公司 | 新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途 |
| JP2023533173A (ja) | 2020-07-09 | 2023-08-02 | エフ． ホフマン－ラ ロシュ アーゲー | タンパク質の濃縮組成物、それらの調製及びそれらの使用 |
| CA3207700A1 (en) * | 2021-01-08 | 2022-07-14 | Nihon Medi-Physics Co., Ltd. | Method for producing ac-225 solution and method for producing medicine using ac-225 solution |
| CN115212308B (zh) * | 2021-04-15 | 2023-10-20 | 中国医学科学院基础医学研究所 | Gasdermin e通路的靶向剂在治疗胰腺癌中的应用 |
| WO2022225007A1 (ja) * | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | 放射性抗腫瘍剤 |
| WO2022239720A1 (ja) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | 抗原への結合親和性を低減させた抗体 |
| JP2024531258A (ja) | 2021-08-13 | 2024-08-29 | クンシャン シンユンター バイオテック カンパニー，リミティド | 微小管阻害剤に基づく抗体薬物複合体 |
| US20240392033A1 (en) | 2021-08-24 | 2024-11-28 | Kunshan Xinyunda Biotech Co., Ltd. | Antibody-drug conjugate conjugated via breakable linker |
| WO2023103854A1 (zh) | 2021-12-09 | 2023-06-15 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4624846A (en) | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
| US4824659A (en) | 1985-06-07 | 1989-04-25 | Immunomedics, Inc. | Antibody conjugates |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| FR2604092B1 (fr) | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5734033A (en) | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US4935498A (en) * | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| US5660827A (en) * | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| WO1993021940A1 (en) | 1992-05-06 | 1993-11-11 | Immunomedics, Inc. | Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| EP0672068A4 (en) | 1992-09-25 | 1997-02-26 | Commw Scient Ind Res Org | TARGET MOLECULES BINDING POLYPEPTIDES. |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| WO1996004925A1 (en) * | 1994-08-12 | 1996-02-22 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| KR100470180B1 (ko) | 1995-06-15 | 2005-02-04 | 크루셀 홀란드 비.브이. | 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템 |
| DE69729283T2 (de) | 1996-03-20 | 2005-05-25 | Immunomedics, Inc. | GLYKOSYLIERTE IgG ANTIKÖRPER |
| CA2253904A1 (en) | 1996-05-03 | 1997-11-13 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
| US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6120995A (en) * | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US7405320B2 (en) * | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| AU1728800A (en) * | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| EP1533380B1 (en) | 1999-04-15 | 2009-11-04 | Crucell Holland B.V. | Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| WO2002068471A2 (en) * | 2000-12-21 | 2002-09-06 | Bristol-Myers Squibb Company | Nucleic acid molecules and polypeptides for a human cation channel polypeptide |
| WO2003059149A2 (en) * | 2001-12-21 | 2003-07-24 | Threshold Pharmaceuticals, Inc. | Methods for cancer imaging |
-
2003
- 2003-06-16 MX MXPA04012656A patent/MXPA04012656A/es active IP Right Grant
- 2003-06-16 EP EP03740743.4A patent/EP1519958B1/en not_active Expired - Lifetime
- 2003-06-16 CN CN038192942A patent/CN1675245B/zh not_active Expired - Fee Related
- 2003-06-16 CA CA2489467A patent/CA2489467C/en not_active Expired - Fee Related
- 2003-06-16 WO PCT/GB2003/002593 patent/WO2003106495A2/en not_active Ceased
- 2003-06-16 ES ES03740743.4T patent/ES2524767T3/es not_active Expired - Lifetime
- 2003-06-16 KR KR1020047020362A patent/KR101143035B1/ko not_active Expired - Fee Related
- 2003-06-16 CN CN2010101460004A patent/CN101824090B/zh not_active Expired - Fee Related
- 2003-06-16 AU AU2003277087A patent/AU2003277087B2/en not_active Ceased
- 2003-06-16 JP JP2004513326A patent/JP5139626B2/ja not_active Expired - Fee Related
- 2003-06-16 US US10/461,885 patent/US7282567B2/en not_active Expired - Fee Related
- 2003-06-16 BR BR0311799-5A patent/BR0311799A/pt not_active Application Discontinuation
- 2003-06-16 EP EP10012295A patent/EP2301968A3/en not_active Ceased
-
2007
- 2007-09-04 US US11/849,791 patent/US20080050311A1/en not_active Abandoned
-
2008
- 2008-09-10 AU AU2008212083A patent/AU2008212083B2/en not_active Ceased
-
2010
- 2010-04-13 JP JP2010092200A patent/JP5155356B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006513695A5 (enExample) | ||
| JP2006507803A5 (enExample) | ||
| US11230609B2 (en) | Humanised anti kallikrein-2 antibody | |
| JP5161254B2 (ja) | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 | |
| JP4963512B2 (ja) | 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造及び使用 | |
| JP4455322B2 (ja) | 二重特異性抗体ならびにキャリアペプチドと活性薬剤を含むハプテン構築物を用いる薬物プレターゲッティング | |
| CN101824090B (zh) | 人源化单克隆抗体hPAM4 | |
| KR101228124B1 (ko) | 단클론 항체 ｐａｍ4 및 췌장암의 진단 및 치료를 위한이들의 용도 | |
| JP2006516086A5 (enExample) | ||
| JP5919604B2 (ja) | 抗膵癌抗体 | |
| JP6289733B2 (ja) | 癌の予防及び／又は治療に用いるための放射標識抗体断片 | |
| JP2006502091A (ja) | クリアランス速度を高めるための二重特異性抗体点変異 | |
| JP2009531031A5 (enExample) | ||
| JP2013512920A5 (enExample) | ||
| US20120034158A1 (en) | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis corresponding compositions and kits | |
| JP2014524902A5 (enExample) | ||
| TWI879889B (zh) | 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途 | |
| CN116194133A (zh) | 抗gd2 sada缀合物及其用途 | |
| JP7708374B2 (ja) | フィブリンに結合する抗体および当該抗体を含む医薬組成物 | |
| JP2016515093A (ja) | 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤 |